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Pilot Study of Behavioral Activation as Adjunct Treatment for Depression in Primary Care 
 
Lindsay E. Toler 
 
          Many individuals receiving care at a predominantly free primary health care clinic in the 
northern part of West Virginia are experiencing depression, and medication therapy is the most 
common form of management with limited resources for psychosocial treatment. Brief 
psychosocial therapy interventions provided by the primary care provider should be explored as 
an adjunct treatment for this population in the primary care setting. 
          A pilot study was conducted to explore the integration of behavioral activation, a brief 
psychosocial intervention focused on decreasing depressed behavior by increasing nondepressed 
behavior to reinforce corresponding improvements in mood. Eligible patients were invited to 
attend five sessions once for five weeks. Visits were conducted according to the revised manual 
for Behavioral Activation Treatment for Depression. Data collection included measurements for 
adherence to treatment, PHQ-9, and BADS scores.  
          Three primary aims were evaluated for this project: 1) To assess the feasibility of 
implementing this intervention in this clinic population; 2) To decrease overall PHQ-9 scores and 
increase overall BADS scores; and 3) To increase medication adherence in conjunction with a 
psychosocial intervention.  
          The feasibility evaluation of this project was performed according to Bowen’s feasibility 
criteria and showed mixed results. Data suggests there was no statistically significant difference 
in depressive symptoms or daily functioning but minor improvements were noted, indicating 
potential clinical significance. Limitations of this study included low patient enrollment and the 
COVID-19 pandemic. Future research could include implementation of this intervention in an 
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          Depression is a prevalent illness in West Virginia (WV DHHR, 2018). Many individuals 
receiving care at a predominantly free primary health care clinic in the northern part of the state 
are experiencing depression, and medication therapy is the most common form of management 
as there are limited resources for treatment like psychiatry or formal counseling. Despite 
medication management, a noticeable amount of depression screenings for ongoing monitoring 
show moderate to severe depression scores without improvement. Psychosocial therapy 
delivered by primary care providers should be explored as an adjunct treatment for this 
population in primary care settings. Current practice must be modified to improve depressive 
illnesses and their sequela in this population as patients with untreated depression suffer from 
greater comorbidities and earlier mortality than their non-depressed counterparts (Coryell, 2018). 
Background 
          A diagnosis of major depressive disorder (MDD) requires the presence of five or more 
symptoms over a two-week period that include either depressed mood or anhedonia (American 
Psychiatric Association [APA], 2013). People with major depression may experience a lack of 
interest or pleasure in daily activities, significant weight loss or gain, insomnia or excessive 
sleeping, lack of energy, inability to concentrate, feelings of worthlessness or excessive guilt, 
and recurrent thoughts of death or suicide (American Psychological Association, 2020). 
According to the Center for Disease Control (CDC, 2015) between the years 2013 and 2016, 
8.1% of Americans aged 20 and older were diagnosed with depression. 





          The lifetime prevalence of major depression in the United States is 17% (Krishnan, 2019). 
The prevalence of depression in West Virginia is significantly higher at 23.8% (WV DHHR, 
2018). Depression is associated with coronary heart disease (CHD), diabetes mellitus (DM), 
Parkinson’s disease (PD), stroke CVA), and dementia (Coryell, 2018). These associations could 
be due to the disease process itself or impaired functioning related to the disease (Krishnan, 
2019). Depression is also associated with earlier mortality. People with serious mental illnesses 
die about 25 years earlier than the general population (Mauer, 2006). Studies show that the 
likelihood of mortality due to any cause is about 50 to 100 % greater in depressed individuals, 
compared with nondepressed individuals (Coryell, 2018). Death due to suicide, homicide, and 
accidental death is also increased in patients with depression (Coryell, 2018). The most recent 
data from the CDC for West Virginia shows a steady increase in deaths associated with suicide, 
homicide, firearms, and overdoses during the years 2014 to 2017 (CDC, 2018). These statistics 
indicate a significant need for increased access to treatment for depression in West Virginia. 
          Center for Disease Control statistics demonstrate a correlation between depression and 
socioeconomic status. This data shows that 15.8% of adults from families living below the 
federal poverty level have depression, but the prevalence of depression decreases as family 
income levels increase (Brody, Pratt, & Hughes, 2018). In West Virginia, depression is 
significantly higher among people with less than a high school education and an annual 
household income of less than $15,000 (WV DHHR, 2018). In a sample of patients with a lower 
socioeconomic status at a free, rural, primary care clinic in West Virginia, 39% of patients had a 
diagnosis of depression (McCrone et al., 2007). Factors predictive of depression were younger 
age, lower education level, alcohol use, and unemployment (McCrone et al., 2007). Services for 





communication, December 15, 2019); however, low availability of resources such as funding and 
transportation make the likelihood of success for outpatient psychiatry referrals unreliable. 
Moreover, West Virginia is not prepared to meet the need for specialty treatment of mental 
illness. The state ranks 49th in mental health workforce availability with one provider for every 
890 patients (Hellebuyck, Halpern, Nguyen, & Fritze, 2019). According to the CDC, 10.4% of 
all primary care visits were used to address depressive symptoms (2015). They also note that 
between the years 2011 and 2014, 12.7% of people aged 12 and older used antidepressant 
medication (Pratt, Brody, & Gu, 2017). Amidst the current treatment options in primary care, the 
rate and severity of depression appear to be increasing (WV DHHR, 2018). 
           Due to this shortage of mental health providers, psychosocial treatments for depression 
should be considered for integration into primary care services. Treatments must be timely and 
providers must be easily trained to enhance feasibility and engagement. While cognitive-
behavioral therapy is the gold standard for depression, it requires a significant time commitment 
and must be implemented by providers with specialty training. Behavioral therapy is not a novel 
treatment, but interest in its usefulness and simplicity has been recently renewed. The behavioral 
approach was pioneered by Ferster (1973) and Lewinsohn (1974), both of whom recognized a 
link between avoidant behavior and depression. They recommended the use of behavioral 
activation strategies to increase positive reinforcement with the environment and subsequently 
improve mood (Ferster, 1973 & Lewinsohn, 1974). There are two current evidence-based 
methods for behavioral activation strategies: Behavioral Activation and the Brief Behavioral 
Activation Treatment for Depression (Turner & Leach, 2012). Behavioral activation strategies 
emphasize the importance of reinforcement as a means of treatment (Turner & Leach, 2012). 





nondepressed behavior to reinforce the corresponding improvements in mood that these actions 
produce (Turner & Leach, 2012). During treatment with behavioral activation, the provider 
works with the patient to identify patterns of reinforcing behavior and the contingencies between 
those behaviors and their consequences (Turner & Leach, 2012). With activation techniques, an 
automatic consequence of increasing positively reinforcing behaviors results in the decrease of 
negatively reinforcing behaviors that perpetuate depressive symptoms (Turner & Leach, 2012). 
Behavioral activation itself involves collaboration between provider and patient to identify 
behaviors that elicit and reinforce depressive symptoms, and then choosing positive behaviors 
for activation (Turner & Leach, 2012). Due to its simple, straightforward technique and 
implementation without complex training, behavioral activation has the potential to be a valuable 
treatment for depression in primary care. 
Problem Statement 
          Patients with a lower socioeconomic status tend to have an increased rate of depression 
(Brody, Pratt, & Hughes, 2018; WV DHHR, 2018). At a rural, predominantly free, primary care 
clinic in northern West Virginia, a large percentage of patients with these characteristics are 
diagnosed with depression (McCrone et al., 2007). Screening during treatment often reflects little 
to no improvement in depression scores (C. Wang, personal communication, December 15, 
2019). Due to a lack of resources, referral to higher levels of specialty care is often impractical. 
Changes in clinician practice are being explored to address persistent depressive symptoms. 
Purpose of Project 
          This pilot study implemented the Brief Behavioral Activation Treatment for Depression in 





symptoms and improve patient behaviors associated with depression. Implementing behavioral 
activation as part of depression treatment in a low socioeconomic status population at a primary 
care clinic had the potential to improve depression outcomes. 
Literature Review 
          An advanced literature search was conducted on December 14, 2019 using EbscoHost. 
Most notable databases included were Cochrane Library, CINAHL, Medline PubMed, and 
PsycINFO. Searches included various combinations of key words “behavioral activation,” 
“Behavioral Activation for Treatment of Depression,” “primary care,” “primary care clinic,” and 
“depression.” Inclusion criteria were human subjects, English language, and publication between 
2000 and 2019. Exclusion criteria included studies on forms of depression other than major 
depressive disorder, depression associated with other illnesses, and studies with an adolescent 
and/or child population. After duplicates were removed and inclusion and exclusion criteria were 
applied, nine articles were found suitable for review (see Appendix A for evidence table with 
more complete study details).  
          The first article chosen for review was a randomized control trial by Dimidjian et al. 
(2006) comparing behavioral activation, cognitive therapy, anti-depressant medication (ADM), 
and placebo control (PLA). The purpose of this study was to assess the effectiveness of 
behavioral activation (BA) as a treatment for major depression compared to cognitive therapy 
(CT) and ADM in the presence of a placebo control. Participants were randomly assigned to a 
treatment group using a computer-generated randomization list. Treatment groups consisted of 
BA, CT, ADM, or PLA. Severity of depression was used as a stratification of randomization. 
There was significant overall improvement across all conditions in the high-severity subgroup on 





significantly more per week than participants in the CT condition on the BDI (p = 0.029) and the 
HRSD (p = 0.03). Patients in the ADM condition also improved significantly more per week 
than participants in the CT condition on the BDI (p = 0.007) and the HRSD (p = 0.022). No 
significant differences were found comparing participants in the BA and ADM conditions on 
BDI or HRSD. There were significant overall improvements across all conditions in the low-
severity subgroup on the BDI (p < 0.0001) and the HRSD (p < 0.0001), but there was no 
evidence of differences in improvement between treatments on the BDI or HRSD. For rates of 
response in the high-severity subgroup, data showed that significantly more participants in the 
BA condition met response criteria compared to those receiving CT (p = 0.048) or ADM (p = 
0.027). For rates of remission in the high-severity subgroup, data showed significant differences 
between treatments on the HRSD (p = 0.012) and a significantly greater percentage of remission 
for participants in the BA condition compared with participants in the ADM condition (p = 
0.002). From these findings, authors concluded that BA is similarly efficacious to ADM and 
more effective than CT. In more severely depressed patients, BA treatment resulted in a 
significantly larger number of participants reaching remission, and keeping a higher percentage 
of patients in treatment. These results highlight the importance of simple behavioral strategies in 
the treatment of depression. 
          The next article for review is a meta-analysis conducted by Cuijpers, van Straten, and 
Warmerdam (2007). The purpose of this meta-analysis was to examine the effects of activity 
scheduling (AS) on depression, the effects of activity scheduling compared to other treatments, 
and the long-term effects of activity scheduling. The literature included 16 studies with a total of 
780 participants for this meta-analysis.  Results showed that the mean effect size between 





effect size between activity scheduling and other psychological treatments was small, favoring 
activity scheduling but without a significant difference. The pooled effect size between activity 
scheduling and cognitive therapy was small, favoring activity scheduling. The pooled effect size 
between activity scheduling and a combination of CT and AS was small, favoring the 
combination of CT and AS. The pooled effect size between CT and a combination of CT and AS 
was small, favoring the combination of CT and AS. The effect size between activity scheduling 
and antidepressant medication was small, favoring activity scheduling. The effects of activity 
scheduling compared to a control condition at follow-up was large at two months and moderate 
at six months, suggesting some corroboration for the effectiveness of activity scheduling at long-
term follow-up. The effect size between activity scheduling and CT at 1-2 months and 4-6 
months was small, indicating nonsignificant differences between CT and activity scheduling at 
follow-up. From this data, authors concluded that activity scheduling is effective in the treatment 
of depression in adults. The overall effect size of activity scheduling is large, and similar to 
effect sizes found for other psychological treatments and antidepressants. 
          The next article for review is a meta-analysis by Ekers, Richards, and Gilbody (2007). The 
purpose of this study was to compare the effectiveness of behavioral therapy (BT) interventions 
to other psychosocial treatments and control conditions. Twenty studies were included with a 
total of 1,109 participants. Interventions in these studies included BT, treatment as usual (TAU) 
or control condition, CBT/CT, brief psychotherapy, or supportive counseling. Results for studies 
comparing BT and control conditions showed a significant difference between symptom level 
scores favoring BT over control (p < 0.001). There were also significantly larger rates of 
recovery in BT conditions than control (p = 0.03). Results for studies comparing BT and 





studies comparing BT and brief psychotherapy showed a significant difference between 
symptom level scores favoring BT over psychotherapy (p = 0.01). There were significantly 
higher rates of recovery observed in the BT condition than psychotherapy (p = 0.01). Results for 
studies comparing BT and supportive therapy showed a significant difference between 
conditions favoring BT (p = 0.02). From these results, authors conclude that BT is an effective 
treatment for depression and is superior to control conditions, supportive counseling, and brief 
psychotherapy. Authors also concluded that BT and CBT resulted in equivalent results with no 
statistically significant differences in post-treatment and follow-up symptom levels, recovery 
rates, or drop outs. These findings indicate that BT is as effective and acceptable as CBT/CT. 
The authors mention that data from this study did not support the assumption that BT may afford 
shorter training of less-qualified individuals to relieve the burden on therapist availiabity and 
demand; however, a meta-regression examining the impact of level of training for delivery of BT 
did not find that superior outcomes were associated with higher level of qualifications. Overall, 
authors conclude that BT is an effective treatment for depression with equal, or better, outcomes 
than treatments currently recommended. 
          The next article for review by Dobson et al. (2008) is a randomized control trial that builds 
on the findings of the RCT by Dimidjian et al. published in 2006. The purpose of this study is to 
determine the sustained effectiveness of prior CT, BA, or continued ADM in the presence of a 
placebo control, and whether the effects of CT or BA extended into the second year of follow-up. 
This study measured the rates of relapse or recurrence of depression in the participants of the 
Dimidjian et al. study. Assessments were conducted biweekly for the first two months of the 
first-year follow-up phase, and then at three, six, 12, 13, 14, 18, and 24 months. Data showed 





withdrawn onto placebo. Rates of relapse during the first follow-up year showed that active 
treatments (CT, BA, or ADM) resulted in significantly lower rates of relapse than withdrawal to 
placebo (p = 0.04). Taken individually, prior CT was significantly better than withdrawal to 
placebo (p = 0.02) and prior BA resulted in lower rates of relapse at a nonsignificant level (p = 
0.09). Rates of relapse were not significantly different between continued ADM and withdrawal 
to placebo (p = 0.33). Prior exposure to CT reduced the risk for relapse by 64% compared to 
medication withdrawal, while continued ADM reduced the risk for relapse by about 33%, and 
prior exposure to BA reduced the risk for relapse by 51%. Participants in the continued ADM 
condition were withdrawn to placebo at the beginning of the second-year of follow-up. Rates of 
recurrence during the second-year of follow-up were lower in the prior CT and BA conditions 
than prior continued ADM but not with a significant trend (p = 0.06). Overall, prior CT and BA 
were significantly superior to continuation of ADM (p = 0.04) and medication withdrawal. Prior 
exposure to CT was significantly superior to continued ADM (p = 0.02) and prior exposure to 
BA showed a nonsignificant trend in the same direction (p = 0.08). From these results, authors 
concluded that prior exposure to either CT or BA resulted in an ongoing effect that was at least 
as effective as continued medication treatment, including the prevention of relapse and possibly 
recurrence. 
          The next article for review is a randomized control trial by Gawrysiak, Nicholas, and 
Hopko (2009). The purpose of this study was to assess the effectiveness of a single-session BA 
intervention based on the BATD protocol. Participants were recruited online from an 
introductory psychology course at a Southeastern university. Eligible participants who agreed to 
take part in the study were randomly assigned to the treatment or control group. The intervention 





The treatment was reduced from a nine-session protocol to one session, which resulted in 
decreased activity scheduling and exclusion of behavioral contracting strategies. Outcome 
measures were assessed using the BDI, to measure depression symptom severity, the EROS, to 
measure environmental reward and response-contingent positive reinforcement (RCPR) with 
higher scores suggesting increased environmental reward, the BAI, to measure symptoms of 
anxiety, and the MSPSS, to measure the social support from participants’ family and friends, 
with higher scores indicating decreased social support. The authors also measured adherence to 
treatment using the weekly behavioral checkout sheets that participants returned to clinicians at 
the follow-up visit. Analysis showed a significant interaction between Group x Time on both the 
BDI (p < 0.01) and EROS (p < 0.001) and large effect sizes on the BDI (1.61) and EROS (1.14) 
demonstrated clinically significant improvements. There was a trend toward greater social 
support in the treatment group relative to control at post-treatment (p = 0.08) with a moderate 
effect size (d = 0.70). Reliable change indices were calculated for each measure and showed that 
93% of individuals in the BATD group significantly improved on the BDI compared with 31% 
in the control group, that 64% of individuals in the BATD group significantly improved on the 
EROS compared to 0% of participants in the control group, and that 29% of individuals in the 
BATD group significantly improved on the MSPSS compared with 6% in the control group. 
Change-score data showed a strong relationship between increased environmental reward with 
decreased depression (p < 0.01), anxiety (p < 0.05), and increased social support (p < 0.01). 
Authors concluded that there was evidence that a brief BA intervention was effective in reducing 
depressive symptoms, increasing response-contingent positive reinforcement, and increasing 
social support. Data shows that a single-session of the BATD intervention resulted in significant 





shortened treatments may be effective and efficient in reducing depressive symptoms of 
moderately depressed students. 
          The next article for review is a meta-analysis by Mazzucchelli, Kane, and Rees (2009). 
The purpose of this meta-analysis was to identify all randomized control trials (RCT) of 
behavioral activation (BA), establish the effect of this method, and compare the effectiveness of 
its variants. Interventions included pleasant activities, self-control, contextual behavioral 
activation, and Behavioral Activation Treatment for Depression (BATD). Comparators included 
nontreatment, cognitive behavioral therapy/cognitive therapy (CBT/CT), and a blanket group of 
other treatments such as psychodynamic therapy or supportive counseling. After exclusion, 34 
studies with a total of 2,055 participants were chosen. Results showed a large overall effect size 
in patients with elevated scores of depressive symptoms favoring BA over control conditions. 
This finding is similar to previous meta-analyses. Results also show a large, significant overall 
effect size favoring BA in patients meeting criteria for depressive disorder. However, 
comparisons between BA and CBT/CT showed no difference at post-test or follow-up, indicating 
that these treatments were equally effective in the short- and long-term. From the evidence, 
authors concluded that BA interventions are effective for the treatment of depression in adults, 
and the behavioral activation approach could be designated as a well-established treatment for 
depression. 
          The next article for review by Richards, et al. (2016) is a randomized, controlled, open-
label, noninferiority trial. The purpose of this study was to assess clinical efficacy and cost-
effectiveness of BA intervention compared to CBT in adults with depression. Patients were 
randomly assigned to treatment groups using computer-generated randomization and were 





recruitment site. The BA intervention was delivered to participants by junior Mental Health 
Workers (MHWs) and the CBT intervention was delivered by experienced psychologists. 
Follow-up assessments were conducted at six, 12, and 18 months. The primary outcome measure 
was self-reported depression severity using the PHQ-9 at 12 months. Secondary outcome 
measures included PHQ-9 scores at six and 18 months, diagnostic status, number of depression 
free days between follow-up points as determined by structured clinical interview, and health-
related quality of life at six, 12, and 18 months using a 36-Item Short Form Survey. The 
modified intention-to-treat (mITT) population is comprised of all participants randomized with 
complete data and the per-protocol (PP) population was comprised of participants randomized 
with complete data who completed at least eight treatment sessions. Authors found no evidence 
of inferiority between these two populations. Authors also found no evidence of a significant 
between-group treatment interaction across the mITT or PP group for the primary outcome at 12 
months as stratified by depression severity, antidepressant use, and recruitment site. Data showed 
that BA was not significantly different from CBT with relation to anxiety, depression status, 
depression-free days, or anxiety diagnoses for either the mITT or PP populations at 12 months. 
Data also showed that 61% to 70% of mITT and PP participants in both treatment groups met the 
criteria for recovery from depression with response to treatment at 12 months. Authors found no 
evidence of a difference between the BA and CBT groups with a nonsignificant time by 
treatment effect interaction for both mITT and PP populations. Authors did find a significant 
difference in average cost for intervention between the two groups in favor of BA (p < 0.0001), 
but no differences between categories of cost (hospital care, community health care, or 
medication) or in total cost. The mean health-related quality of life score was slightly higher for 





(QALY) also higher for participants in BA. Authors concluded that BA treatment for depression 
is non-inferior to CBT in terms of reduction in depressive symptoms and is more cost-effective 
than CBT treatment. Overall, authors believe that the results of this study challenge the 
dominance of CBT due to findings that suggest therapies that can reduce the need for costly 
professional training, reduce patient waiting times, and increase access to psychological 
therapies. 
          The next article for review is a benchmark-controlled trial (BCT) by Luoto et al. (2018). 
The purpose of this study is to examine the effects of BA in a group of depressed patients in their 
natural treatment setting and compare them to treatment as usual with regard to functional 
recovery, service use, dropout rate, and mortality. After matching, authors found that statistically 
significant differences between groups were baseline Global Assessment of Functioning (GAF) 
scores and frequency of personality disorders as a secondary diagnosis. BA treatments were 
implemented by trained personnel, including registered psychiatric nurses, psychiatric practical 
nurses, and psychologists. Follow-up appointments were scheduled with a clinical research nurse 
at six, 12, and 24 months after intervention. Patients in the control group received TAU 
according to the protocols of their specific interventions and follow-up data was gathered from 
patient case-notes at six, 12, and 24 months after treatment by estimating GAF scores and 
obtaining information about alcohol use. For treatment and control conditions, data concerning 
frequency of outpatient visits, number of hospital days, and dropout rates were obtained from 
patient records at six, 12, and 24 months following treatment. Results showed that mean scores 
for participants in the treatment group on MADRS at baseline was 23.2 points, 13.1 points at 6 
months, 9.93 points at 12 months, and 8.31 points at 24 months. The improvement of MADRS 





Again, for treatment group participants there was no difference in GAF scores between baseline 
and follow-up at six months. However, at 12- and 24-months follow-up the estimated 
improvement in GAF scores was significantly better in the intervention group (p = 0.036). Data 
showed no between-group differences in number of outpatient visits during any follow-up 
period. The need for hospitalization was similar between treatment and control groups during all 
follow-up periods. There were no differences between treatment and control groups with regards 
to dropout rates in any follow-up period (p = 0.79, p = 0.86, p = 0.51, respectively). During all 
follow-up periods, there was no significant difference in mortality between groups (p = 0.23). 
Authors consider this study to be highly representative of the standard patient population in 
natural practice settings. Due to this capability for generalization, they believe conclusions are 
useful in real world practices. Data from this study shows that depressive symptoms of 
participants in the treatment group seemed to improve at follow-up periods, and the authors 
believe that BA may be a useful tool for treatment. Authors also noted that participants in the 
treatment group showed a greater improvement in functional ability than those in the control 
group and believe this is essential to patients’ daily life. Rates of hospitalization and dropout 
were not significantly different between treatment and control groups. Overall, authors found an 
improvement in depressive symptoms and a trend toward functional recovery in patients treated 
with BA compared to TAU. 
          The last article for review by Funderburk, Pigeon, Shepardson, and Maisto (2019) was a 
non-randomized, non-controlled intervention trial. The purpose of this study was to address the 
need for a brief depression treatment suitable for primary care. Data showed a significant 
reduction in depressive symptoms based on PHQ-9 scores (p = 0.001). Data also revealed patient 





completed activity logs. A CSQ rating of 26.7 out of 35 indicated a high level of patient 
satisfaction, including satisfaction with the number, duration, and format of appointments. 
Authors concluded that results of the study supported the feasibility, acceptability, and efficacy 
of BA-PC. Patients reported high levels of satisfaction with the intervention, high likelihood of 
continuing activity scheduling after treatment, and perceived improvements in depressive 
symptoms which was supported by a decrease in PHQ-9 scores. Authors do admit that BA-PC 
may not entirely resolve depressive symptoms, and that a majority of patients did not report a 
clinically significant reduction in symptoms as defined by their criteria; however, a 68% 
treatment response showed a majority of patients reported symptom reduction. Summarily, this 
study showed BA-PC was well received by patients, could be delivered with high fidelity, and 
may result in an improvement of depressive symptoms. 
Literature Synthesis 
          This review produced studies that were mostly located in the upper tiers of evidence-based 
literature with a majority being randomized control trials or meta-analyses. All articles were 
published in peer-reviewed journals lending credibility to study findings. They were also 
replicable and generalizable. While not all studies found behavioral activation to be superior to 
cognitive-behavioral therapy or cognitive therapy, all studies found BA to be equivalent to 
CBT/CT. All studies also found BA to be superior to placebo, control, antidepressant 
medication, and other forms of psychosocial intervention. 
Theoretical Framework 
          This project was based on the Theory of Symptom Management. The Theory of Symptom 





2001. According to the theory, signs and symptoms of illness disrupt functioning and bring 
patients into the health care system, usually after self-care management strategies fail. This 
theory proposes a relationship between three concepts, provides a structure to understand the 
relationship between concepts, and provides a framework for considering interventions and 
outcomes (Smith & Liehr, 2008). 
          The Theory of Symptom Management is composed of three concepts. These concepts 
include symptom experience, symptom management strategies, and symptom status outcomes. 
Symptom experience is the “simultaneous perception, evaluation, and response to a change in 
usual feeling” (Smith & Liehr, 2008, p. 147). If a symptom occurs with enough frequency and 
severity to be perceived as distressing and interfering with life, the patient will seek help for 
more effective ways to minimize or stop the symptom. Symptom management strategies are 
“efforts to avert, delay, or minimize symptom experience” (Smith & Liehr, 2008, p. 147). 
Management strategies are effective by reducing frequency of symptom experience, minimizing 
severity of symptom experience, and relieving the distress associated with symptom experience. 
Symptom status outcomes are specific, measurable outcomes that are evaluated after the 
implementation of a strategy. Outcomes are obvious changes in symptom status where the 
symptom is less frequent, intense, or distressing (Smith & Liehr, 2008). 
          This theory is a framework for the study and development of symptom management 
strategies and apply to this project. Theoretically, patients with low socioeconomic status will 
experience depressed mood, anhedonia, and other symptoms of depression (Brody, Pratt, & 
Hughes, 2018). These symptoms cause the patient to suffer some type of distress. They then try 
to manage or eliminate this distress on their own but frequently visit their primary care provider 





been shown to alleviate or eliminate symptom experience. In this situation, it seems that typical 
management strategies are not adequate to improve symptom experience. Successful 
interventions by the primary care provider should improve the distress of depression symptoms. 




          Treatment guidelines from the National Institute for Health and Care Excellence recognize 
that BA is an effective treatment for depression and should be considered as an intervention for 
patients with depressive symptomology ([NICE], 2009). This pilot study evaluated the 
effectiveness of the revised Behavioral Activation Treatment for Depression (Lejuez, Hopko, 
Acierno, Daughters, & Pagoto, 2011) combined with treatment as usual implemented in a 
predominantly free primary care clinic in northern West Virginia serving a population of 
individuals with a low socioeconomic status. 
          The intervention used in this pilot study was a shortened version of the revised Behavioral 
Activation Treatment for Depression (BATD-R) by Lejuez, Hopko, Acierno, Daughters, and 
Pagoto (2011). Direction was taken from the revised treatment manual. Specific revisions to the 
revised treatment include greater emphasis on treatment rationale, more clarity on life areas, 
values, and activities, simplified and fewer treatment forms, enhanced procedural details, and a 
revised daily monitoring form for low literacy (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 
2011). The original procedure in its extended format consists of 10 sessions. These meetings 





(Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011). Studies have shown the effectiveness of 
BA in as little as one to two sessions (Gawrysiak, Nicholas, & Hopko, 2009; Funderburk, 
Pigeon, Shepardson, & Maisto, 2019) which led this intervention to consist of the five active 
sessions from the BATD-R treatment manual according to instruction. Sessions took place 
during 60-minute appointments once weekly for five weeks. This intervention took place at a 
predominantly free primary care clinic in northern West Virginia where appointment length is 
usually 60 minutes.  
          Patients with a provider appointment set between April 26, 2020 and July 24, 2020 were 
screened for eligibility by the provider using the electronic medical record. Eligibility criteria for 
patient participation was a diagnosis of major depressive disorder or elevated depressive 
symptomology as evidenced by answering yes to either question on the PHQ-2. Exclusion 
criteria included participation in any other psychosocial treatment. Each patient who agreed to 
take part in the project was asked to sign an informed consent document. 
          During the first treatment session, each patient completed a Patient Health Questionnaire-9 
(PHQ-9) and Behavioral Activation for Depression Scale (BADS) questionnaire. Throughout 
treatment, patients completed Daily Monitoring Forms (DMF), the Life Areas, Values, and 
Activities Form (LVAF), the Activity Selection and Ranking Form (ASRF), and Contract Forms 
(CF). The DMF is a table that allows the patient to track their daily activities (see Appendix B). 
The LVAF is a form the patient can use to identify their values in certain life areas and specific 
activities that support these values (see Appendix C). The ASRF is a form the patient uses to 
choose activities that support their values and then ranks these activities by difficulty (See 





friends in their treatment (Appendix E). Each session in the revised manual was accompanied by 
a completion checklist for the provider. 
          Each session in the revised manual was accompanied by a completion checklist for the 
provider. 
• Session one included a discussion of depression, introduction to treatment rationale and 
the daily monitoring form, and important points about the structure of treatment. 
• Session two included reviewing and troubleshooting the DMF, reviewing the treatment 
rationale, and completing the LVAF. 
• Session three included reviewing DMFs, reviewing the LVAF, and completing the 
ASRF. 
• Session four included reviewing DMFs and starting daily monitoring with planning 
activities. 
• Session five included reviewing DMFs with activity planning, completing the CFs, and 
completing a DMF for the week with activity planning. 
• Subsequent sessions included the continuation of review and activity planning. 
           Data from the completed PHQ-9 and BADS questionnaires pre- and post-intervention 
were kept in a data table using random patient identification numbers, accompanied by a separate 
master list. (Refer to Appendix F for data table.) This data table and master list was kept in a 
locked box with a key kept by the project leader. All other documents completed by the patient 
were stored in their electronic medical record. 
          Participating patients were supposed to attend five 60-minute sessions over the course of 





a checklist for each session to ensure adherence to treatment. It was intended for each patient to 
complete a post-treatment PHQ-9 and BADS during the last treatment session. Patients who 
failed to attend at least three out of five treatment sessions were considered lost to follow-up.  
Feasibility Analysis 
          The goal of this pilot study was to implement a behavioral activation intervention in the 
primary care setting to improve the management of depression. It was implemented in a 
community funded clinic that services low income, uninsured and underinsured patients. This 
clinic is housed in the center of an urban area where most community resources reside for the 
impoverished population. These resources include multiple food pantries and soup kitchens, a 
drop-in center, homeless shelter, and department of human resources. The clinic itself serves as a 
meeting place for a large portion of this population since most of the homeless population can be 
found in this area. A significant number of patients who attend this clinic pass through multiple 
times a day. While the location of this clinic is ideal for its population, most specialty clinics can 
only be accessed using automotive transportation. Patients at this clinic rarely have funds for bus 
rides, car services, or personal vehicles. Most patients will usually request continued treatment at 
the primary care clinic. 
          In order to provide comprehensive behavioral activation treatment, one provider spent 
about 60 minutes per session for a varying number of sessions with five patients. The provider 
saw patients during usual clinic visits and evaluated PHQ-9 scores during the patient assessment 
so provider salary was by the clinic as an organizational contribution. The budget for 





          Educational materials were available for the provider. The provider had a copy of the 
BATD-R treatment manual. Session checklists from the treatment manual were used for each 
individual patient. The scripts for depression discussion and treatment rationale from the first 
session of the treatment manual were printed for each patient to use for discussion. Allowing for 
error in printing, the budget for educational materials totaled approximately $45 from the project 
leader’s personal funds. 
          Project supplies consisted of necessary materials for project intervention. These supplies 
included two copies of the PHQ-9 and BADS, one daily monitoring form, one Life Areas, 
Values, and Activities form, one Activity Selection and Ranking form, and two contract forms 
per patient. These documents were kept in individually labeled file folders and all were kept in a 
locked box. Pens were available for use by participating patients. Estimations take into account 
printing errors. The budget for project supplies totaled approximately $75 from the project 
leader’s personal funds. 
          The budget for this project totaled approximately $3,120. A majority of this budget was 
collected from an organizational contribution and the rest from the project leader’s personal 
funds. This includes monetary provisions for administrative costs, educational materials, and 
project supplies. Implementation and organizational costs to the clinic were minimal since the 
project leader is employed by the clinic and the intervention will be reimbursable as a normal 
clinic visit. Contributions from the clinic were reflected as a portion of the current salary of the 
provider already in place for provision of care. Return on investment was minimal for the clinic 
due to the number of uninsured patients, but some income was generated by billing these visits 
for Medicaid patient participants. However, insurance status was not considered when recruiting 





          There were a few identifiable potential barriers to this project. The first potential barrier 
was the need for increased appointments with the patient. The author considered that increasing 
the number of follow-up appointments might put undue pressure on patients in this population 
and lead to failed outcomes. This is similar to the barrier of patient compliance. As with most 
populations, compliance with an aggressive treatment is likely to be low since it requires 
increased patient effort and participation. The last barrier is patient literacy, including health 
literacy. Patients in a low SES population tend to have low literacy levels, including health 
literacy. This potentially impacted patient understanding of the disease process and treatment 
rationale, and their ability to use written forms for monitoring. This last potential barrier was 
addressed in the revised manual of BATD. 
Evidence of Site Support 
          Support for this project was provided by the administration and clinical staff at the clinic 
of interest. The clinic director gave written approval for the project to take place at the clinic. 
Refer to Appendix G for evidence of site support. 
Timeline 
          Planning for this project started in August of 2019. The study was enrolled in IRB and 
approved in April of 2020. It was also enrolled in the Clinical Trials Center of Excellence and 
the protocol was approved in July of 2020. Implementation began near the end of April 2020 
during the COVID-19 pandemic and was completed near the end of July 2020. Due to issues 
arising from the pandemic, enrollment in the project was extended by four weeks. The project 
was concluded in August 2020. Refer to Appendix H for evidence of timeline. 





          The first aim of this project was to assess the feasibility of implementing this intervention 
in this clinic population with a large percentage of patients struggling with mental illness, who 
were potentially homeless, had a low income, and were either uninsured or underinsured. There 
were five feasibility measures as denoted by Bowen et al. (2009) that were used as measurable 
objectives for this aim: acceptability, demand, implementation, practicality, and limited-efficacy 
testing. Acceptability is the extent to which an intervention is judged as suitable to the patient 
and was measured by the intent to continue use of the intervention (Bowen et al., 2009). Demand 
is the extent to which an intervention is likely to be used and was measured by the expressed 
interest in the intervention and its actual use (Bowen et al., 2009). Implementation is the extent 
to which an intervention is successfully delivered to patients and was measured by the success or 
failure of its execution (Bowen et al., 2009). Practicality is the extent to which an intervention 
can be carried out using the existing resources and was measured by the ability of the 
participants to complete intervention activities (Bowen et al., 2009). Limited-efficacy testing is 
whether or not the intervention can be successful in the intended population and was measured 
by the presence of the intended effects on key variables (Bowen et al., 2009).  Data gathered 
from implementation of the intervention and patient participation was used to assess these 
objectives. 
          The second aim of this project was to decrease overall PHQ-9 scores and increase overall 
BADS scores using a psychosocial intervention. There were two measurable objectives for this 
aim: patients with depression will show a decrease in overall PHQ-9 scores post-intervention, 
and patients with depression will show an increase in BADS scores post-intervention. Data for 
these objectives were measured using self-report information from the PHQ-9 questionnaire and 





for all patients, and after intervention for some patients. A paired t-test was used to determine if 
there was a statistical difference between the pre- and post-data. 
          The third aim of this project was to increase medication treatment adherence in 
conjunction with a psychosocial intervention. There was one measurable objective for this aim: 
patients with depression will show an increase in medication treatment adherence post- 
intervention. Data for this objective was supposed to be measured using self-report information 
and pill counts during the first follow-up visit.  
Data Analysis 
          Once post-treatment questionnaires were completed, data analysis began. Overall PHQ-9 
and BADS scores were calculated for pre- and post-intervention data. Paired t-tests were used to 
determine differences between them. Adherence to treatment by provider was measured using 
checklists from each session to determine percentage of completion. 
Results 
Participation Summary 
          Patients were eligible for participation if they had a diagnosis of major depressive disorder 
or elevated depressive symptomology as evidenced by answering yes to either question on the 
PHQ-2. Exclusion criteria included participation in any other psychosocial treatment and 
individuals less than 18 years of age. Five eligible patients agreed to participate in the study. Ten 
eligible patients declined to participate in the study. All other patients with a diagnosis of MDD 
or depressive symptomology were being seen by a counselor for other psychosocial treatment, 






Patient Number x 
Number of Sessions 
Pt. 1 Pt. 2 Pt. 3 Pt. 4 
Sn. 1 X X X X 
Sn. 2 X  X  
Sn. 3 X    
Sn. 4 X    
Sn. 5 X    
 
          Four patients were enrolled in the project study, and one patient made a verbal 
commitment with a scheduled appointment to start the study. The first patient completed five 
sessions of BATD-R and elected to continue with several sessions. The second patient completed 
one session of BATD-R and then declined further participation. This patient has not been seen in 
the clinic since the first session of BATD-R and no reason was given for discontinuing treatment. 
The third patient completed two sessions of BATD-R, but the next session was cancelled by the 
clinic due to COVID. The subsequent follow-up appointment was cancelled by the patient. Upon 
resumption of treatment, this patient elected to postpone further follow-up due to a recent death 
in the family. The fourth patient completed one session of BATD-R, but the next session was 
cancelled by the clinic due to COVID. The patient then missed the next clinic appointment and 
was unable to be reached by phone later in the week after rescheduling. This patient has not been 
seen in the clinic since missing the follow-up appointment. The fifth patient did not attend the 






Demographic Data Summary 
          Demographic data was obtained for three of the five participants. The second patient did 
not provide demographic data and the fifth patient was not seen for the initial visit when 
demographic data collection takes place. Demographic data included age, gender, ethnicity, level 
of education, employment, housing, tobacco use, drug use, and alcohol use. Patients ranged in 
age from 27 to 61 years old. Two patients were female, two patients are male. Three patients 
considered themselves white. Level of education ranged from ninth grade to some college. Two 
patients were unemployed, one patient was employed. Three patients lived with another person. 
Two patients rented their residence and one patient owned their residence. Two patients lived in 
a house and one patient lived in an apartment. Two patients smoked cigarettes and one patient 
did not use tobacco. Two patients used illicit drugs and one patient did not. Two patients did not 
use alcohol and one patient did use alcohol. 
Evaluation Results 
Aim 1 –   The first aim of this project was to assess the feasibility of implementing this 
intervention using five measurable objectives: acceptability, demand, implementation, 
practicality, and limited-efficacy testing. Acceptability is the extent to which an intervention is 
judged as suitable and was measured by the intent of participants to continue use of the 
intervention. Only one participating patient attended the five required sessions of BATD-R, 
while one patient completed two sessions, two patients completed one session, and one patient 
completed zero sessions. The patient who completed five sessions elected to continue with 
several sessions of BATD-R after the first five sessions. No other participants elected to continue 





          Demand is the extent to which an intervention is likely to be used, and was measured by 
the expressed interest in the intervention and its actual use. Fifteen patients were eligible for the 
project intervention, but only five elected to participate. Of those five patients, four attended at 
least one session. This indicates that 33% of eligible patients expressed interest in the 
intervention, and 80% of those who expressed interest completed at least one session. However, 
only one patient completed all treatment sessions out of the five patients who expressed interest. 
This means that only 20% of the patients who expressed interest completed the intervention.  
          Implementation is the extent to which an intervention is successfully delivered to patients 
and is measured by the success or failure of its execution. Session checklists provided in the 
BATD-R manual were kept for each patient during sessions. Each checklist showed that all 
elements of each session were completed with the patient. This indicates that 100% of the 
required components for treatment were delivered to patients during treatment sessions. 
          Practicality is the extent to which an intervention can be carried out using the existing 
resources and is measured by the ability of the participants to complete intervention activities. 
Participants were expected to complete one Daily Monitoring Form every day, one Life Areas, 
Values, and Activities Form, one Activity Selection and Ranking Form, and at least one Contract 
Form. Patients were provided with one copy of each form, and expected to secure their own 
further copies of daily monitoring forms. Revised versions of the DMF for low literacy 
participants were offered to each patient, but all patients declined. Out of the four patients who 
attended the first session, three were capable of completing the DMF. This indicates that 75% of 
participating patients could use the DMF. One patient had difficulty with the DMF because she 
was illiterate. This indicates that 25% of participating patients could not use the DMF. Out of the 





second exhibited some confusion at using the form. This indicates that 50% of the participating 
patients could use the LAVF form while 50% could not use the form. Of the one patient who 
completed the other three sessions, there was no difficulty in using the ASRF or the CFs. This 
indicates that 100% of the participating patients could use the ASRF and the CFs. 
          Limited-efficacy testing refers to whether or not the intervention can be successful in the 
intended population and is measured by the presence of the intended effects on key variables. 
Results for the effects of the intervention on key variables is limited due to high attrition rates 
and missing data. From the complete pre- and post-data of one patient who completed the 
intervention, there was a decrease in the PHQ-9 score and increase in the BADS score. From the 
partial pre- and post-data of one patient who completed two sessions of the intervention, there 
was an increase in the PHQ-9 score. There were no comparable data sets for the remaining three 
participants. This indicates that the intervention had the intended effect on key variables in 25% 
of the participating patients who completed at least one session. 
Aim 2 –   The second aim of this project was to decrease depression scores and increase daily 
functioning scores as measured by the PHQ-9 and BADS questionnaires. Due to attrition, only 
one patient completed pre- and post-data for both PHQ-9 and BADS questionnaires, while one 
patient completed pre- and post-data for the PHQ-9 questionnaire. The average pre-intervention 
PHQ-9 score for all participating patients was 15.25, while the average pre-intervention BADS 
score for the same patients was 19. The average post-intervention PHQ-9 score for two of the 
four participating patients was 12. Missing data did not allow for an average of the post-
intervention BADS score of participating patients. In the patient that completed the intervention, 
the pre-intervention PHQ-9 score was 19 and the post-intervention score was 9. In this same 





patient that completed two sessions of the intervention, the pre-intervention PHQ-9 score was 14 
and the post-intervention score was 15. A paired t-test was used to compare pre- and post-
intervention scores for two participating patients on the PHQ-9. There was no significant 
difference between the pre- and post-intervention PHQ-9 scores with p = 0.563. However, PHQ-
9 and BADS scores showed clinically significant improvements in depressive symptoms and 
daily functioning in the patient who completed the intervention. The PHQ-9 scores showed no 
clinically significant differences in the patient who completed two sessions of the intervention. 
Aim 3 –   The third aim of this project was to increase medication treatment adherence in 
conjunction with a psychosocial intervention. This data was unable to be collected and the 
provider was unable to determine if there was a statistical difference between the pre- and post-
data. 
Discussion and Recommendations 
          The theoretical framework for this project was based on The Theory of Symptom 
Management. This theory provides a framework for exploring the relationship between 
interventions and outcomes, as outlined by the structure of the association between symptom 
experience, symptom management strategies, and symptom status outcomes (Smith & Liehr, 
2008). According to The Theory of Symptom Management, patients experience distressing 
symptoms and seek symptom management strategies that are followed by an evaluation of 
symptom status outcomes where the symptom should be less frequent, intense, or distressing 
(Smith & Liehr, 2008). The development, implementation, and evaluation of interventions is 
supported by this framework due to its association between the concepts of symptoms, as 





project as it focuses on the evaluation of symptom outcomes after implementing an intervention 
for symptom relief. 
          The feasibility evaluation of this project showed mixed results. Data suggests that the 
intervention was not acceptable to the patient population, nor in high demand. Only a small 
number of eligible patients were interested in the intervention, and an even smaller amount 
actually participated in the sessions. Of those interested, only one patient completed the 
intervention. While data for implementation suggests the intervention can be successfully 
delivered, practicality seemed to be an issue. Completing the included intervention activity forms 
was essential to success of the treatment and patients seemed to struggle with understanding the 
required forms. Limited efficacy data also suggested that this intervention may not produce the 
expected improvement in symptoms of depression or daily functioning in this population. 
          Producing adequate data for analysis of significance was difficult due to patient attrition. 
Available data suggested there was no statistically significant difference in depressive symptoms 
or daily functioning between pre- and post-intervention. Yet data did indicate a potential clinical 
significance. The patient who completed two sessions of the intervention did not show a 
clinically significant difference in depressive symptoms; however, data from the patient that 
completed the intervention in its entirety suggested a clinically significant improvement in 
depressive symptoms and daily functioning after the intervention. 
          While there were some promising findings, it is recommended that this project be phased 
out and terminated at this facility. The feasibility of this project in a population of low income, 
uninsured and underinsured patients is questionable. Patient interest in this behavioral treatment 
was limited and data showed no statistically significant improvement in depression or 





Patient interest in mental health treatment may have been eclipsed by the COVID-19 pandemic 
at this time. It could also account for the attrition rate of participating patients. When speaking of 
attrition, it is important to note that patients with mental illness are more likely to miss follow-up 
appointments, and those that miss follow-up appointments have a greater chance of losing 
contact with the clinic (DeFife, Conklin, Smith, & Poole, 2010; Killaspy, Banerjee, King, & 
Lloyd, 2000). These factors may have had an impact on the implementation of this project. It 
may be possible to implement this project in a behavioral health center or integrated care center, 
or a different primary care clinic with a population of patients that are more likely to attend 
frequent clinic visits. Patients attending a behavioral health center may be more likely to 
continue follow-up while patients at an integrated care center would receive comprehensive care 
that may encourage continued clinic contact. Research literature shows that behavioral activation 
is an effective treatment for depression but this project demonstrates that it may not be 
appropriate in a low-income primary care clinic, especially during the COVID-19 pandemic. 
          The implementation of this project has positively impacted the care I provide for patients 
with mental illness. The research undertaken during the planning phase of this project has 
allowed me to more thoroughly understand the assessment and diagnosis of depression. It has 
also allowed me greater knowledge of the available treatments for depression and their relative 
effectiveness. The therapeutic relationships I built during the implementation phase of this 
project has led me to greater empathy and compassion for patients with mental illness. Greater 
understanding of the patients’ experience has improved my communication and allowed for 
enhanced patient motivation. While analyzing feasibility and outcomes of this project during the 
resolution phase I was able to better understand what patients desire from their treatment plan 





suggest that patients in this population desire more of a therapeutic approach and are not highly 
engaged in treatment activities. This realization led me to increase my use of motivational 
interviewing techniques leading patients to higher levels of engagement and change. These 





















          This project meets the first essential of “scientific underpinnings for practice” by using 
nursing theory to evaluate practice approaches in a novel environment. Using the Theory of 
Symptom Management, this psychosocial intervention was further developed and its 
effectiveness validated in the primary care setting. 
          This project meets the second essential of “organizational and systems leadership for 
quality improvement and systems thinking” by developing and evaluating care for certain 
vulnerable populations. This psychosocial intervention has been revised for patients with mental 
illness who belong to a low socioeconomic status or lack adequate healthcare coverage. 
          This project meets the third essential of “clinical scholarship and analytical methods for 
evidence-based practice” by critically appraising existing literature and using synthesized 
information to design and implement methodologies that promote effective patient care. The 
literature review of this psychosocial intervention preceded the revision of intervention 
guidelines which were implemented to promote patient wellness.  
          This project meets the fourth essential of “information systems/technology and patient care 
technology for the improvement and transformation of health care” by demonstrating the ability 
to develop and execute an evaluation plan using data extraction from practice information 
systems. Completed health questionnaires used to evaluate the effect of this intervention became 
part of the patient’s medical chart, and data from these documents were used to evaluate 
intervention efficacy. 
          This project meets the fifth essential of “health care policy for advocacy in health care” by 





the potential to become part of treatment guidelines for this population and become institutional 
policy at primary health care clinics. The findings from this project can help to improve the 
implementation of this intervention. 
          This project meets the sixth essential of “interprofessional collaboration for improving 
patient and population health outcomes” by using effective communication and collaboration in 
the development and implementation of practice guidelines. The project leader improved the use 
communication skills to educate clinic providers and clinic staff on the use of this intervention 
and encouraged collaborative teamwork to make it successful. 
          This project meets the seventh essential of “clinical prevention and population health for 
improving the nation’s health” by including education as part of the intervention to promote 
healthy behaviors that have an effect on population health. Using a psychosocial intervention, 
this project promoted healthy behaviors in depressed patients that have an effect on this 
particular population. 
          This project meets the eighth essential of “advanced nursing practice” by demonstrating 
advanced levels of clinical judgment, systems thinking, and accountability in designing, 
delivering, and evaluating evidence-based care to improve patient outcomes by designing, 
implementing, and evaluating a psychosocial intervention in primary care. The project leader 
revised the design, implemented, and evaluated an evidence-based psychosocial intervention that 
can improve patient outcomes. 
          Nurses are known to value the holistic well-being of their patients. They establish 
therapeutic relationships that promote a mutual trust and respect between patient and nurse. This 





participation in treatment. This is a unique attribute of the advanced practice nurse. The 
intervention utilized in this study was a direct reflection of that partnership between provider and 
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To examine the 
effects of activity 
scheduling on 
depression, the 
relative effects of 
activity scheduling 
compared to other 









Central Register of 
Controlled Trials. 
Collected primary 






of 777 studies and 
selected ones 
which focused on 
activity scheduling. 
Included studies in 
which effects of 
activity scheduling 
on adults with a 
depressive disorder 
or an elevated level 
of symptomology 
were compared to 




treatment in a 
randomized control 







activities and the 
increase of positive 
interactions 
between a person 
and his/her 
environment were 
the core elements 
of the treatment. 
Methodological 
quality of the 
studies was 
assessed using 4 
criteria by Higgins 
& Green (2005). 
Calculated effect 




16 studies with a 













The pooled effect 
size between activity 
scheduling and other 
psychological 
treatments was 0.13 






The pooled effect 
size between activity 
scheduling and 
cognitive therapy 
was 0.02 indicating a 
small effect favoring 
activity scheduling.  
 
The pooled effect 
size between activity 
scheduling and 
CT+AS was -0.01 




The pooled effect 
size between CT and 
a combination of 
CT+AS was -0.16 








medication was 0.26 
indicating a small 
effect in favor of 
activity scheduling. 
 
The effects of activity 
scheduling compared 
to a control condition 
at follow-up ranged 
from 0.88 at two 
months to 0.54 at six 
months indicating a 












size of 0.87 is 
large and 
comparable 












to CT and 
indicated that 





periods up to 



















support for the 
effectiveness of 
activity scheduling in 
the long-term.  
 
The pooled effect 
size was 0.18 




up. The change 
between post-test 
and 4-6 months 
follow-up resulted in 
a pooled effect size 
of 0.03 indicating a 
small effect. The 
change from post-
test to 7-12 months 
follow-up was 0.53, 
indicating a 
moderate effect.  
 
Effects of activity 
scheduling at follow-
up could be 
compared to the 
effects of CT at 1-2 
months with a 
pooled effect size of 
0.02. Effects of 
activity scheduling at 
follow-up compared 
to CT at follow-up at 
4-6 months had a 




CT and activity 
scheduling at follow-
up. CT vs. activity 
scheduling at one 



















To test the relative 
efficacy of BA in 
acute treatment of 
major depression by 
comparing it both 
with CT alone and 
with ADM in the 
context of a placebo-
controlled trial; to 
test whether either 
psychosocial 
treatment was a 
viable alternative to 
ADM in the 
treatment of 







assigned to a 




consisting of BA, 
CT, ADM, or PLA. 
Depression severity 







consisted of 241 
individuals 
between ages of 
18 and 60 years 
who met criteria 
for major 
depression 
according to the 
DSM-IV and 
scored 20 or 
higher on BDI-II 
and 14 of greater 








by time for all groups 
on the BDI and on 
evaluator rated 
HRSD, p < 0.0001. 
Participants in BA 
improved 
significantly more per 
treatment than in CT 
on both BDI 
(p=0.029), and the 
HRSD (p=0.038). 
Participants in ADM 
improved 
significantly more per 
treatment than in CT 
Results of this 
study indicate 
that BA is 
comparable 





















medication (ADM) or 








were used to form 
two groups of high 








max of 24, 50-min 
sessions over 16 
weeks, generally 
held twice weekly 
for first 8 weeks 
and once weekly 
for second 8 
weeks. CT 
condition followed 






as the BA 
condition. Both 
ADM and PLA 
conditions were 
administered in a 
triple-blind manner 
during first 8 weeks 
then the blind was 
broken and PLA 
participants were 
offered their choice 
of treatment at 
study expense. 
ADM was 
administered in a 
single-blind 
manner for the 
final 8 weeks. 
Participants were 
seen weekly for the 
first 4 weeks and 
biweekly thereafter 
through week 16 
(although PLA were 
terminated at week 
8). First 
pharmacotherapy 
session was 30-45 
min and 
subsequent 
sessions lasted up 
to 30 minutes. 
Diagnosis was 





using a modified 
17-item version of 
the HRSD and the 
occurred 
between 1998 









excluded if they 









risk, current or 
primary diagnosis 
















adequate trial of 
CT or paroxetine 
within the 
previous year. 
on both BDI 
(p=0.007) and HRSD 
(p-0.022). No sig diff 
in the rate of 
improvements 
between BA and 
ADM on BDI or HRSD 
(p=0.80, p=0.96). 
Using the BDI and 
HRSD, ADM and BA 
lie within the margin 
of noninferiority, 
with a probability 
larger than 99.1%.  
In low-severity 
subgroup, there was 
significant overall 
improvement by time 
for all groups on the 
BDI (p<0.0001) and 
the HRSD (p<0.0001). 
No evidence of 
differential 
improvement over 
time by treatment on 




combined rates of 
response and 
remission based on 
the BDI were 48% in 
CT, 76% in BA, and 
49% in ADM. On the 
basis of HRSD overall 
rates were 56% in CT, 
60% in BA, and 40% 
in ADM. Significantly 
greater percentage of 
BA participants met 
BDI response criteria 
compared with 
receiving CT 
(p=0.048). Rates of 
remission high-
severity subgroup 
based on BDI were 
40% in CT, 52% in BA, 
and 42% in ADM. On 
basis of HRSD, overall 
rates of remission 
were 36% in CT, 56% 
in BA, and 23% in 
ADM. No significant 
differences between 




treatments on the 
HRSD (p=0.012) with 
a significantly greater 






























































well in this 
study. It was 








BDI-II. HRSD was 
administered at 
pre-, mid-, and 
post-treatment and 
as required. HRSD 
was administered 
at each session 
during the first 8 









measured using a 






inclusion of BA, and 
Cognitive Therapy 
Scale for 







the point of being 
asymptomatic 
within normal 
range. On HRSD 
and BDI, response 
was defined as at 
least 50% reduction 
from baseline and 
remission was 
defined as scores 
less than or equal 
to 7 on HRSD and 
10 on the BDI.  
remission as 
compared with ADM.  
Among less severely 
depressed, overall 
rates of response 
based on BDI were 
65% in CT, 50% in BA, 
and 56% in ADM. On 
basis of HRSD overall 
response rates were 
60% in CT, 39% in BA, 
and 47% in ADM. No 
significant 
differences between 
treatments on BDI. 
Rates of remission 
based on BDI were 
55% in CT, 44% in BA, 
and 42% in ADM. On 
basis of HRSD overall 
rates of remission 
were 50% in CT, 39% 
in BA, and 33% in 
ADM. No significant 
difference between 





















Interest in BA 
was based in 
part on the 
notion that it 




that is easier 
to implement 
and train 

















enduring effects of 
prior exposure to BA, 
prior exposure to CT, 
and continued 
treatment with ADM 
in the context of a 
placebo-controlled 
trial. To determine 





relapse to the 
prevention of 
recurrence during a 
2nd year follow-up 
after acute 
Participants were 
recruited from the 
original Dimidjian 
(2006) study and 
consisted of 106 
patients who had 
been assigned to 
active treatment 
but no longer met 
the diagnostic 
criteria for MDD at 
the end of the 
acute phase of 
treatment. Data 
were available to 
estimate risk to the 
point of relapse or 
recurrence for 92 
of the 106 patients 
Participants were 
followed to the 
point of relapse 
or recurrence for 
















likely to occur at the 
start of the 1st follow-




placebo (cPLA). Rates 
of relapse during 1st 
follow-up year were 
39% for prior CT, 50% 
for prior BA, 53% for 





placebo (p = 0.04). 









CT or BA has 
an enduring 
effect that is 

















is defined as the 
return of the treated 
episode of 
depression, and in 
this study as either 
HRSD scores of 14 or 
greater or PSRs of 5 
or greater for 2 
successive weeks 
during the 1st year of 
follow-up. 
Recurrence is 
defined as the onset 
of a new episode of 
depression, and in 
this study as either 
HRSD scores of 14 or 
greater or PSRs of 5 
or greater for 2 
successive weeks 





PLA at the 
beginning of the 





Patients in cADM 
and cPLA 
continued to see 
pharmacotherapi
sts biweekly for 
the first 2 months 
and monthly 
thereafter the 
rest of the 1st 
year follow-up. 






the same taper 
as used for cPLA 
participants. 
Patients in both 
cADM and cPLA 
were seen 
biweekly during 
the taper period 
and then 
assessed during 





biweekly for the 
first 2 months of 
the 1st year 
follow-u phase, 
at months 3, 6, 
and 12, 13, 14, 
18, and 24. Ad 
hoc assessments 
were conducted 
whenever a new 
episode of 
depression was 
suspected, on the 
basis of elevated 
HRSD scores, or 
patient or 
pharmacotherapi
st report.  
was significantly 
superior to cPLA (p = 
0.02) and prior BA 
demonstrated a 
nonsignificant trend 
(p = 0.09), but cADM 
was not significantly 
different from cPLA 
(p = 0.33). Prior 
exposure to CT 
reduced risk for 




reduced risk for 
relapse by about 
33%. Prior exposure 
to BA was associated 
with a reduction in 
risk for relapse by 
51%, and is 






in cADM were 
withdrawn from 
medication at the 
beginning of 2nd year 
follow-up. Rates of 
recurrence during 2nd 
follow-up year were 
24% for prior CT, 26% 
for prior BA, and 52% 
for prior cADM. 
Effect of prior CT and 
BA showed a 
nonsignificant trend 
compared to the 
effect of prior cADM 
(p = 0.06). Prior 
exposure to either CT 
or BA reduced the 
risk of recurrence by 
about 63% relative to 
medication 
withdrawal. The 
overall effect for 
treatment was 
significant (p = 0.04) 
with both prior CT 





withdrawal. Prior CT 
was significantly 
superior to cADM (p 
= 0.02) whereas prior 
BA exhibited a 
nonsignificant trend 
























that BA may 

























relapse. BA is 
implemented 



















(p = 0.08). Prior 
exposure to BA was 
associated with a 
reduction in risk of 
47% relative to cADM 
and prior CT was 
associated with a 
reduction in risk of 
58%. CT and BA were 
directly compared 
with maximal power 
provided by full 2-
year comparison and 
did not significantly 
differ (p = 0.57). CT 
was associated with a 
reduction in risk of 
27% relative to prior 
BA. Over one third of 
patients initially 
assigned to BA/CT 
showed sustained 
outcomes across the 
course of acute 
treatment and the 1st 
follow-up year, 
compared to less 





revealed that only 
prior CT had a 
greater sustained 
response than both 
cADM. Across the 2nd 
follow-up year, rats 
of sustained recovery 
were 35% for prior 
CT and 28% for prior 
BA. This indicates 
that brief treatment 
with either CT or BA 
is as efficacious over 
the long run as 
keeping people on 
ADM. 
evidence that 
they alter the 
















found of a 
preventive 




























and prior BA 
did almost as 
well (at a 
nonsignifican
t level). Each 
was at least 
as effective 
as continued 
medication.   
Ekers, D., 


















AMED, and British 
20 studies, 1109 
subjects 
 
BT vs waiting 
list/control/place




BT vs. Waiting 
list/placebo/control: 




in symptom level 
scores favoring BT (p 




















studies found using 
reference lists. All 
available RCT in 
any language were 
included, 
participants aged > 













included BT (based 
upon rescheduling 







(range of standard 
treatments such as 
waiting list, usual 







































BDI, HAMD, or 
both. 
 
BT vs. CT/CBT: 12 
studies with a 









with six 40-min 












studies with a 












using BDI or BDI 
& HAMD. 
 
BT vs. supportive 
therapy: 2 







ranged from six 
20-min sessions 
to eight 50-min 
sessions. 
Measured 
dropout rate of 
19.17% with no 
differences between 
intervention and 
control (p = 0.86). 
Greater rates of 
recovery in BT (p = 
0.03). 
BT vs. CT/CBT: 
Depression level post 
treatment showed no 
difference in effect 
between BT and 
CBT/CT was 
identified with a 
pooled SMD (p = 
0.46). Depression 
level at follow-up 
showed no difference 
in effect with a 
pooled SMD (p = 
0.28). No difference 
in rates of dropout (p 
= 0.67). Pooled 
recovery rate of 55% 
with no difference 
between treatment 
approaches (p = 
0.72). 
 
BT vs. psychotherapy: 
Depression symptom 
post-treatment 
showed a positive 
effect of BT with a 
large pooled SMD (p 
= 0.01). Depression 
symptom level at 
follow-up showed a 
positive effect of BT 
with a medium SMD 
(p = 0.02). Average 
dropout rate of 
14.45% but no 
difference between 
studies observed (p = 
0.11). Greater rates 
of recovery were 
observed in BT 
compared to 
psychotherapy (p = 
0.01). 
 
BT vs. supportive 
therapy: Depression 
symptom level at 
post-treatment 
showed a positive 
effect of BT against 
supportive therapy 





























, we observed 
no difference 
in recovery or 
dropout, 
indicating 


























We found no 
direct 
evidence in 





















from each trial at 
post-treatment and 
follow-up of 6 
















































R.L., & Maisto, 
S.A. (2019). 
To address the need 



























BA-PC with two 
boosters spaced 2-
3 weeks apart. 
Content was 






Booster appts did 





solved barriers, and 
set new goals.  
Participants were 
recruited from 




on PHQ-2 in the 
previous month 
were identified 









symptoms of at 
least moderate 
severity termed 
PHQ-9 > or = 10, 
no current mania 
or psychosis, no 





the past month, 
no 
antidepressants 
or on stable dose 




logs for 2, 3, & 4 
were 36%, 1%, and 
32% resp. Patients 
tried to enact 1 of 
the goals set at prev 
appt based on 
discuss with mean 




ility: mean CSQ rating 
was 26.7 out of 35 
indicating high level 
of overall satisfaction 
with number & 
duration of appts, 
and in-person 
format. Seven 
patients cited ease of 




likelihood of cont to 
engage in activities 
after study to 
improve mood. 
Treatment response: 















































for anxiety or 


















baseline level of 
depressive 
symptoms. 
p = 0.001. No 
statistically sig 
difference in report 
of morbid/suicidal 
ideation, 6/11 
reported no thoughts 
of suicide in the past 
2 weeks or thoughts 
less often. 
Fidelity: Appt 1 & 2 = 
all core content 
delivered to 95% of 
pts. 26/32 
participants 
completed appts 1 & 
2, and a majority of 
patients (n=20) also 
completed two 
boosters. Average 12 
days between appts, 
appts 1&2 lasted 
average of 34- and 
29-minutes resp. 
Booster appts lasted 























































pts in primary 
care and that 



















To use an RCT to 


















for students in 
need. Participants 





years and older 
who scored 14 or 
higher on the BDI 








if involved with 
psychotherapy 









intervention in that 
it was reduced to a 
one-session 
treatment which 
resulted in five 
fewer weeks of 
activity scheduling 
making it a 
nonprogressive 
approach to 
activating, in which 
a greater number 























All but 2 eligible 
students agreed 
to participate in 





















measured with the 
weekly behavioral 
checkout that was 
returned to clinician 
at post-treatment. All 
outcome variables 
were examined with 
a 2x2 repeated 
measures analysis of 
variance. Clinical 
significance of pre-
post differences was 
assessed using 
Cohen’s d statistic 
where effect sizes of 
0.2, 0.5, and 0.8 are 
considered small, 
medium, and large. 
Significant Group x 
Time interactions 
were evident on both 
the BDI (p < 0.01) and 
EROS (p < 0.001). 
Large effect sizes on 
both the BDI (1.61) 




scores did not yield a 
significant Group x 
Time interaction (p = 
0.25, d = 0.36). A 
trend toward 
increased social 
support in BATD 
group relative to 
control condition at 
post treatment (p = 
0.08) that was 
characterized by a 
moderate effect size 
(d = 0.70). Reliable 
change indices (RCI) 
calculated for each 
measure indicated 
that on the BDI 93% 




with only 31% in the 
control group. On the 
EROS, 64% of 
individuals in the 
BATD group 
improved, where 0% 




change. MSPSS data 
revealed that 29% of 




















































with BA and 
increased 
environment




































had their initial 
session in which 
they were exposed 
to either 90 min of 





in the study. 
Follow-up sessions 
were scheduled 2 





























of anxiety), and 
MSPSS (assesses 
the adequacy of 






compared with only 
6% in the control 
group. RCI analyses 
of the BAI yielded 
comparable findings 
across groups with 
36% of individuals in 
the BATD group and 
31% of participants in 





change scores to 
determine the 
degree to which 
efforts to structure 




effective e in 
reducing depressive 
affect. Although 
causality cannot be 
inferred, change-






reward was strongly 
correlated with 
decreased 
depression (p < 0.01) 
and anxiety (p < 
0.05), as well as 
increased social 


























































A., Lassila, A., 
Leinonen, E., 
& Kampman, 
O. (2018).  
To explore the 
benefits of BA in a 
heterogeneous 
group of depressed 
patients in a 
naturalistic setting 
and to compare BA 
with treatment as 
usual in terms of 
functional recovery, 




used to assess the 
impact of clinical 
intervention in 
routine settings, in 
contrast to RCT 
which usually 
assess the specific 
intervention in 
ideal settings. To 
study the impact of 
the selected 
intervention in real 










with TAU methods 
in the same area. 
Consecutive 
patients who were 










screened using the 
BDI. Those with BDI 
score equal to or 
greater than 17 at 
the screening were 
included in the 
intervention group 
(n = 242). The 
control group (n = 
205) was recruited 
from a hospital 
district database of 
psychiatric 
outpatient clinics 
not participating in 
the ODS study from 
October 2009-
December 2012 
and from the same 
psychiatric hospital 
ward before the 
start of the ODS. 
Patients with a new 















MADRS scores. Mean 
score for intervention 
patients at baseline 
was 23.2 pts, 13.1 at 
6 months, 9.93 at 12 
months, and 8.31 at 
24 months. Change in 
MADRS was 
statistically 
significant in every 
follow-up period. At 
12- and 24-months 
follow-up the 
estimated 
improvement in GAF 
score was 
significantly better in 
the intervention 
group (p = 0.036). At 
six months a similar 








diagnosis (n = 44). 
Results were similar 
with the total sample 
analysis with GAF 
estimates between 
intervention and 
control groups at 6 
months (p = 0.057), 
12 months (p = 
0.006), and 24 
months (p = 0.002). 
There was no 
between-group 
differences in 
number of outpatient 




measured in every 
follow-up period and 
number of 
hospitalized patients 
was similar in the 
intervention and 
control groups during 
all periods. Among 






































































were selected in 
chronological order 
if their BDI score 
was greater than or 
equal to 17 at 
admission and the 
AUDIT score was 
available. Control 
group patients 
were matched with 
the intervention 
group patients by 
clustering 




nt), AUDIT score in 
4 categories, and 
BDI score in 2 
categories. 
Characteristics 
were mainly similar 
between the 
groups, only the 
baseline GAF score 
(p = 0.035) and the 
frequencies of 
personality 
disorders as a 
secondary 
psychiatric 
















disorders in clinical 
settings) and used 
to decide which 










(MADRS) and level 
of functioning was 
assessed using the 
Global Assessment 
baseline, number of 
patients hospitalized 
during follow-up 
periods was also 
similar between 
groups. There were 
no between group 
differences in the 
number of patients 
who dropped out in 
any period (p = 0.79, 
p = 0.86, p = 0.51, 
respectively). There 
were 4 deaths in the 
intervention group 
and 7 deaths in the 














was similar in 
both groups. 










































scale (GAF). For 
control group, all 













used during the 
first appointment 
in patients having 
alcohol use 
problems (baseline 
AUDIT greater than 
or equal to 11). 
Minimum duration 
of BA was set at 4 
appointments. 
Median number of 
sessions was 6.5. 
Decision to start 
medication was 
based on clinical 
evaluation at 
baseline and 6 
weeks by the 
treating physician. 
If baseline MADRS 
score was 20 or 
more, medication 
was started and 
the dose was 
elevated if 
necessary or 
changed from SSRI 
to SNRI as needed. 
All patients in the 
control group were 
treated in public 
psychiatric 
secondary care in 
the same 
organization as the 
intervention group 
over the same time 
period. Control 
patients received 
TAU according to 
protocols of 
respective 
treatment unit and 
followed-up 
according to the 
case notes at 6, 12, 










use. For both 
groups, info about 
frequency of visits, 
number of hospital 
days, and dropouts 
were collected 
from patient 
registers at 6, 12, 
and 24 months 
follow-up.  
Mazzucchelli, 
T., Kane, R., & 
Rees, C. 
(2009). 
To identify all 
randomized 
controlled studies of 
BA, to determine the 
effect of this 

























pleasant events, or 
pleasant activities. 
Studies were 
included if effects 














treatment in a RCT. 
 BA vs. Control 
conditions – The 
effect of BA against 
control was large 
with a pooled effect 




BA. BA vs. Other 
conditions – 
Negligible pooled 




indicated that the 
pleasant activities 
variant of BA yielded 




effect in favor of 
CBT/CT, and 
contextual variant 
yielded small effect 
in favor of BA. Effect 
sizes of different 
variants of BA were 
not found to differ 
significantly from 
each other. Effects at 
follow-up – BA vs. 
control at 1-3 month 
follow-up was large 




BA; at 7-12 month 
follow-up effect was 
small at 0.08 and 
nonsignificant in 
favor of BA. BA vs. 
CBT/CT at 1-3, 4-6, 7-
12, and 13-24 
months effect size 
was small and 
nonsignificant with 
an effect size ranging 
from -0.10 in favor of 
CBT/CT to 0.05 in 















size in favor 
































CBT/CT for up 












other treatments at 
1-3 months showed 
pooled effect size of 
0.23 indicating a 
small, nonsignificant 
difference in favor of 
BA; BA vs. 
psychotherapy only 
at 4-6 and 7-12 
months effect sizes 
were large but 
nonsignificant in 
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To establish clinical 
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effectiveness of BA 
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patient records of 
general practices 
and psychological 






















adults 18 years 
and older who 
met diagnostic 











acute suicidal or 
Between Sept 26, 





participants to the BA 
group and 219 to the 
CBT group. 
Participants received 
an average of 11.5 BA 
sessions or 12.5 CBT 
sessions. Found no 
evidence of 
inferiority between 
mITT or PP 
populations. Found 
no evidence of a 
significant between-
group treatment 
interaction across the 










and is more 
cost-effective 


























to PHQ-9 scores, 
antidepressant 
use/nonuse, and 
recruitment site. A 
computer-based 
system allocated 
the first 20 patients 
to each group on a 









variables across the 
two groups. 
Authors developed 
clinical protocols in 












maximum of 20 
sessions over 16 
weeks, with the 
option of 4 
additional booster 
sessions if desired 
by patients. All 
core components 
of BA & CBT were 
delivered by week 
8. Sessions were in 















suicide in the 
past 2 months, 
cognitively 









for patients with 
depression.  
outcome at 12 




and recruitment site. 
Found that BA was 
not different from 
CBT in anxiety, 
depression status, 
depression-free days, 
or anxiety diagnoses 
for either the mITT or 
PP populations at 12 
months. Between 
61% and 70% of mITT 
and PP participants in 
both groups met 
criteria for recovery 
from depression in 
response to 
treatment at 12 
months with no 
difference in the 
proportions of 
patients in each 
group who recovered 
or responded. Found 
no evidence of a 
difference between 
the CBT and BA 
groups over the 
period of the trial as 
indicated by a 
nonsignificant time 
by treatment effect 
interaction for both 
mITT and PP 




between the two 
groups in favor of BA 
(p < 0.0001), but no 
differences in 
categories of cost or 
in total cost. Mean 
health state utility 
scores according to 
EuroQoL-5D-3L were 
slightly higher in the 
BA group than CBT 
across the entire 




higher for BA, but the 
QALY difference was 
not significant. Costs 
were lower and QALY 
outcomes better in 
the BA group than in 
the CBT group. BA 







that BA is as 
effective as 





















y given the 
greater 
availability 
and ease with 




could a CBT 
workforce. 




































were done at 6, 12, 












PHQ-9 scores at 6 
and 18 months, 
DSM-IV diagnostic 







quality of life at 6, 
12, and 18 months 
(36-item Short 
Form Survey).  
costly than CBT, so 
BA continues to have 
a higher probability 
of being cost-
effective than does 






















































































1 19 17 9 35 -10 +18 
2 12 21 N/A N/A N/A N/A 
3 14 14 15 N/A +1 N/A 
4 16 24 N/A N/A N/A N/A 
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